1 Result: Acelyrin
Acelyrin (SLRN), CRISPR Therapeutics (CRSP), Elevation Oncology (ELEV), STERIS (STE), Teleflex (TFX): Analyst Coverage and Potential Upside Revealed
May 30th, 2023
Acelyrin, Inc. (Nasdaq: SLRN), a pharmaceutical company dedicated to developing innovative therapies, caught the attention of Jefferies, which initiated coverage on the stock with a Buy rating and a price target of $31. Despite $SLRN closing. Read more
Load More Content
Want To Find Some News?
News By Industries
Recent Post
-
Earnings Due: Wall Street Eyes Goldman Sachs, Fastenal, FB Financial
April 12th, 2026Treasury Launches Cybersecurity Information Sharing Initiative for the Digital Asset Industry
April 09th, 2026How Eligibility Protection Is Creating New Opportunities for Football Athletes After High School
April 08th, 2026Cryptocurrency and AI Scams Bilk Americans of Billions
April 06th, 2026
Member Login